ReviewBlood reviews2016
The prothrombotic activity of cancer cells in the circulation.
Review in Blood reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Tailored management of a melanoma patient with bleeding brain metastases and deep vein thrombosis with thrombectomy.CNS oncology · 2026Article
- Thrombin generation profiling in multiple myeloma: a comprehensive evaluation of prothrombotic state.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2026Article
- Circulating tumor cells and circulating tumor microemboli: role in venous thromboembolism in oncologic patients.Bioscience reports · 2026Review
- Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- AI-enabled D-dimeromics in precision breast oncology: a transformative framework for the identification, stratification, and prognostication of ultra-high-risk disease phenotypes.Frontiers in oncology · 2026Review
- Thromboelastographic Assessment of Coagulation Profiles in Dogs with Cardiac Tumors and Their Relationship to Cardiac Function.Animals : an open access journal from MDPI · 2025Article
- Radiotherapy-the not-so-insignificant contributor to cancer-associated venous thrombosis.Research and practice in thrombosis and haemostasis · 2025Review
- Association between tumor markers elevation and poor functional outcomes after acute ischemic stroke: a longitudinal stroke center-based study.Annals of medicine · 2024Article
- Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells.Acta pharmaceutica Sinica. B · 2024Review
- What to Do When There Is Something Unexpected?Life (Basel, Switzerland) · 2024Article
- The role of coagulome in the tumor immune microenvironment.Advanced drug delivery reviews · 2023Review
- The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- Integrated analysis of single-cell and bulk RNA sequencing data reveals an immunostimulatory microenvironment in tumor thrombus of osteosarcoma.Oncogenesis · 2023Article
- The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma.Current oncology (Toronto, Ont.) · 2023Article
- Clinical Validation of a Size-Based Microfluidic Device for Circulating Tumor Cell Isolation and Analysis in Renal Cell Carcinoma.International journal of molecular sciences · 2023Article
- Multi-modal quantification of pathway activity with MAYA.Nature communications · 2023Article
- The Applications and Challenges of the Development ofCellular and molecular bioengineering · 2023Review
- Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.Frontiers in immunology · 2023Review
- Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications.British journal of cancer · 2022Review
- Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The hemostatic system is often subverted in patients with cancer, resulting in life-threatening venous thrombotic events. Despite the multifactorial and complex etiology of cancer-associated thrombosis, changes in the expression and activity of cancer-derived tissue factor (TF) - the principle initiator of the coagulation cascade - are considered key to malignant hypercoagulopathy and to the pathophysiology of thrombosis. However, many of the molecular and cellular mechanisms coupling the hemostatic degeneration to malignancy remain largely uncharacterized. In this review we discuss some of the tumor-intrinsic and tumor-extrinsic mechanisms that may contribute to the prothrombotic state of cancer, and we bring into focus the potential for circulating tumor cells (CTCs) in advancing our understanding of the field. We also summarize the current status of anti-coagulant therapy for the treatment of thrombosis in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.